Ginkgo Bioworks Stock Falls On Disappointing Q1 Sales: 'This Trend Needs To Change'
Portfolio Pulse from Erica Kollmann
Ginkgo Bioworks Holdings, Inc. (NASDAQ:DNA) reported Q1 sales of $38 million, missing analyst estimates by 17.47% and marking a 52.91% decrease year-over-year, primarily due to a ramp down in K-12 testing in its Biosecurity segment. Cell Engineering revenue decreased by 18%, while Biosecurity revenue was $10 million with an 8% gross profit margin. CEO Jason Kelly expressed disappointment and announced a plan for adjusted EBITDA break-even by end of 2026, including significant cost reductions.
May 09, 2024 | 8:50 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Ginkgo Bioworks reported disappointing Q1 sales, missing estimates and experiencing a significant year-over-year decrease. The company announced a strategic plan to reach EBITDA break-even by 2026, including reducing physical footprint and labor expenses.
The significant miss in sales estimates and the year-over-year decrease in revenue are likely to negatively impact investor sentiment in the short term. The announcement of a strategic plan to reduce costs and achieve EBITDA break-even by 2026 may not be sufficient to offset the immediate negative reaction to the earnings miss and revenue decline.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100